Consortia & Funding

Formation of consortia

An important task of CLIB is the active networking of its members, not only in view of business opportunities, but also in the initiation of market-oriented research and innovation projects. Here, we offer assistance with sharpening issues, forming consortia, the selection of appropriate funding opportunities, the proposal application and - where desired - project support.
We also offer optimal conditions for the commercialisation of your project from the patent utilisation to distributors and industrial customers to investors by using our network.  

Forum – Round table - Bilateral talks

The CLIB management welcomes member requests and proposals for interesting topics. It also actively scouts and identifies current and promising topics of biotechnology and related fields and pursues these through a set of customised event formats with the aim of forming consortia. First we invite to a CLIB forum where lectures are given as an impulse to a larger groups of CLIB members and partners, followed by discussions. A get-together completes the event and gives the opportunity to cultivate and initiate contacts. Themes of special interest shown in the forum events will be intensified in smaller CLIB round table discussions, thus offering members the opportunity to discuss in a smaller group. If desired we moderate bilateral talks and can also enter into a confidentiality agreement.

Important for us is the integration of industries not yet involved in biotechnology. We aim not only to identify opportunities offered by technology, but also to identify market requirements. This opens up new chances for our members and networks across value chains.
For current forum topics please visit our event page.

Examples of R&D projects initiated by CLIB (in part funded via the BioIndustrie2021 programme) can be found on our R&D project page.

Your contacts in the CLIB management team are Dennis Herzberg (national funding) and Dr. Tobias Klement (EU funding). Their contacts are available here.